# A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.

> **NCT06632600** · PHASE2 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 130 (estimated)

## Conditions studied

- Chagas Disease

## Interventions

- **DRUG:** LXE408
- **DRUG:** Placebo
- **DRUG:** Benznidazole

## Key facts

- **NCT ID:** NCT06632600
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-28
- **Primary completion:** 2027-03-22
- **Final completion:** 2030-09-21
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06632600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06632600, "A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06632600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*